{"id":"c1280","number":2134,"headline":{"en":"Cancer Treatment Advancements","da":"Fremskridt inden for kræftbehandling"},"content":{"en":"Cancer Treatment Advancements: Treatment algorithms can optimize therapy for multiple myeloma, new molecular techniques can improve patient selection and aid clinical decision-making in cancer treatment, and the shift from risk-led to benefit-led practice affects the treatment strategies for cancer. Modifications to the RECIST criteria can improve the assessment of treatment response in metastatic cancer, molecular targets can be leveraged to personalize systemic therapy in non-small cell lung cancer, and historical benchmarks can be used for survival analysis in metastatic pancreatic cancer. These are just a few examples of how algorithms are being used to improve cancer treatment and patient outcomes.","da":"Fremskridt inden for kræftbehandling: Behandlingsalgoritmer kan optimere terapi for multipel myelom, nye molekylære teknikker kan forbedre patientudvælgelse og hjælpe med klinisk beslutningstagning i kræftbehandling, og overgangen fra risikobaseret til fordel-baseret praksis påvirker behandlingsstrategier for kræft. Ændringer i RECIST-kriterierne kan forbedre vurderingen af behandlingsrespons i metastatisk kræft, molekylære mål kan udnyttes til at personliggøre systemisk terapi ved ikke-småcellet lungekræft, og historiske benchmarks kan bruges til overlevelsesanalyse i metastatisk bugspytkirtelkræft. Dette er blot nogle få eksempler på, hvordan algoritmer bruges til at forbedre kræftbehandling og patientresultater."},"bots":{"critic":{"en":null,"da":null},"potential":{"en":null,"da":null}}}